CytomX Therapeutics, Inc. · Brief

Next report

5 days

Nov 5 · after closeest.Q3 FY26

Expected move

±4.8%implied · report alone

2.232.45

straddle ±34.5%

spot 2.34exp Nov 20ATM strike 2ATM straddle 0.95IV 216%

Oct 30 closereport share · term structure

Expected move

—≥ implied

Q2 FY26±14.0%▲+2.67%×0.19

quarterimplied−15%0+15%realized×

Q2 FY26±14.0%▲+2.67%×0.19

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 5 report · est.

Bull2 of 3

10disclosed supplier and customer ties in SEC filingsSEC filings

4tracked funds holding CTMXN-PORT · Aug 31 '26

Bear2 of 3

0.28%largest tracked fund weight in State Street SPDR S and P Biotech ETF assetsN-PORT · Jun 30 '26

8 of 25largest reporting managers that cut their stake in the latest quarter13F · Jun 30 '26

AI captions · Oct 26 '26once per report · top 2 per case

CTMX report session

No linked exposure.

Oct 22impliedImplied move: ±40.6% into Nov 5 earnings (Oct 22 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.